Loading…
← CockpitCompetitor Analysis › 1066.HK Shandong Weigao Group Medical Polymer Co. Ltd. Class HOpen in the cockpit ↗

Shandong Weigao Group Medical Polymer Co. Ltd. Class H1066.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties

Chinese maker of disposable medical devices and consumables, including orthopedic implants, syringes and infusion products.

≈ China's answer to a diversified Becton Dickinson/Medtronic-lite medical device makerMomentum strong 61
Mkt cap
$1.82B
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$5.39M
20-day average traded
Fwd P/E
8.2×
forward earnings
ROIC−WACC
-0.6 pp
WACC 6.8%
Hurdle
-15 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · HKDHK$3.17
1D-3.0%
1W-4.1%
1M-5.2%
3M-8.8%
6M-7.7%
YTD-36.8%
1Y-40.9%
ATR %3.2%
52w lowhigh45.5% off high

What Shandong Weigao Group Medical Polymer does

Chinese maker of disposable medical devices and consumables, including orthopedic implants, syringes and infusion products.

Sells disposable consumables through distributors and hospital tenders, a business of high volumes and steady repeat use. China's volume-based procurement, national bulk tenders in which the lowest bids win large orders, has pushed down prices on implants and other devices, so winning tenders matters.

In one line: China's answer to a diversified Becton Dickinson/Medtronic-lite medical device maker.

Products and services

  • Disposable medical consumables (syringes, infusion sets)
  • Orthopedic implants
  • Blood management products
  • Interventional/cardio devices

Customers

  • Hospitals and healthcare providers in China

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Disposables & orthopedic implants

What could go right

  • China hospital equipment/consumables demand growth

What could go wrong

  • China's centralized volume-based procurement (price cuts)
  • Product-registration/regulatory risk

Moat: narrow (scale, regulatory licence, distribution). Broad product registrations and a large domestic distribution network across China's hospital system.

Headquarters: Weihai, Shandong, China · Founded: 1988 · Employees: 13,307

Named competitors

Shandong Weigao Group Medical Polymer at a glance

Size Shandong Weigao Group Medical Polymer (1066.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $1.82B, the 429th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.17 on 18 Nov 2026.

Performance Over six months the shares fell 7.7%, against +3.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 7.5% over the last twelve months (peer median +14.5%); the operating margin is 13.6% (peer median 14.6%).

Valuation It trades at 8.2× forward earnings against a peer median of 25.1× (2nd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.6 points below its cost of capital (6.8% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 1021066.HK 92
Six months, rebased to 100: Shandong Weigao Group Medical Polymer against the median of its 20 peers (local-currency closes).

Shandong Weigao Group Medical Polymer financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$15.2BHK$14.5BHK$14.2BHK$14.6BHK$16.0B
Revenue growth—+2%-3%-9%—
Gross profitHK$6.67BHK$6.60BHK$6.82BHK$7.04BHK$8.20B
EBITDAHK$3.20BHK$3.10BHK$3.59BHK$3.50BHK$4.56B
Net incomeHK$1.54BHK$1.75BHK$2.24BHK$2.21BHK$3.21B
Free cash flown/aHK$1.99BHK$2.17BHK$2.04BHK$1.42B
Capital expendituren/aHK$903MHK$702MHK$758MHK$1.30B
Total debtn/aHK$6.59BHK$5.45BHK$5.26BHK$5.36B

Quarterly statements and history in the cockpit →

Shandong Weigao Group Medical Polymer competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%6960268ASKANPOLYMEDMED7716CHEMMLMAT301363EMBLAKMTSINSP8086BFLY6699BONEXVCYT3010871066.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Weigao Group Medical Polymer is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%20×40×60×6960268ASKANPOLYMEDMED7716CHEMM301363EMBLAXRAYINSP6699BONEXVCYT3010871066.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Weigao Group Medical Polymer is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6960268ASKAN7716LMAT301363EMBLAXRAYINSP6699BONEXVCYT3010871066.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Weigao Group Medical Polymer is the large dot.

Shandong Weigao Group Medical Polymer competitors and peer comparison

Head to head with its named competitors (1066.HK vs BDX vs MDT vs 0853.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shandong Weigao Group Medical Polymer 1066.HK$1.82B-8%+7%14%8.2×-12.6%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
MicroPort Scientific 0853.HKn/a-45%n/an/an/an/a

How Shandong Weigao Group Medical Polymer compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Weigao Group Medical Polymer against its 20 peers (data as of 18 Nov 2026)
Measure1066.HKPeer medianRank in peer set
1-month return-5.2%-4.4%10th lowest of 21
6-month return-7.7%+3.5%8th lowest of 20
Distance from 52-week high-45.5%-21.0%5th lowest of 21
Revenue growth (TTM)+7.5%+14.5%7th lowest of 21
Operating margin13.6%14.6%10th lowest of 21
Forward P/E8.2×25.1×2nd cheapest of 18
Growth the price implies (Req g, 7 yrs)-12.6%13.2%least demanding of 15
Growth delivered (Del g)+2.1%+13.5%3rd lowest of 15
Hurdle (Req g minus delivered)-14.8 pp-4.8 pp5th least demanding of 15
ROIC minus cost of capital-0.6 pp+2.2 pp9th lowest of 21
EV / EBITDA3.7×17.9×cheapest of 16
Net debt / EBITDA-1.5×-0.8×6th least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%

Questions

Who are Shandong Weigao Group Medical Polymer's main competitors?
Named competitors: Becton Dickinson (BDX), Medtronic (MDT), MicroPort Scientific (0853.HK). The cockpit's measured peer set (industry) also includes Fukuda Denshi (6960.T), Rigaku (268A.T), Molbio Diagnostics (MOLBIO.NS), SKAN (SKAN.SW), Poly Medicure (POLYMED.NS), Medartis (MED.SW).
Is Shandong Weigao Group Medical Polymer expensive compared with its peers?
On forward p/e it trades at 8.2× against a peer median of 25.1×, 2nd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has Shandong Weigao Group Medical Polymer stock performed?
Over six months to 18 Nov 2026 the shares returned -7.7% against +3.5% for the median peer; over one year -40.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.